OpenAI Researcher Set to Launch AI Drug Discovery Startup

From Chatbots to Pharmaceuticals

In a move that reflects the accelerating shift toward AI applications in the life sciences, Miles Wang, a researcher at OpenAI, is preparing to leave his prominent employer and found a startup specializing in leveraging AI models for drug discovery. According to sources familiar with his plans, a number of fellow researchers from the same organization are expected to join him.

Funding and Valuation Details

Available information indicates that Wang is currently in talks to raise approximately $200 million at an overall valuation of $2 billion. Lightspeed Venture Partners is leading the discussions as the potential lead investor in the round. Negotiations are still ongoing and have not yet been formally concluded, and Wang has pushed back on some of the figures and details circulating without clarifying the correct information.

The Core Idea: Reviving Existing Drugs

What sets this venture apart from just another AI company is its potential focus on drug repurposing — searching for new therapeutic uses for drugs that have already received FDA approval, and potentially re-evaluating compounds that failed in previous clinical trials. This approach offers a fundamental advantage in that it:

• Bypasses the lengthy safety-testing phases required for entirely new drugs.
• Significantly accelerates the path to revenue generation.
• Reduces the costs and risks associated with developing therapeutic compounds from scratch.

An Early Career and Research Achievements

Wang joined OpenAI in 2024 after leaving his undergraduate studies at Harvard University, where he was pursuing a degree in computer science. Despite his young age, during his time there he co-authored research papers examining AI models' ability to automate and accelerate scientific discovery — giving him a solid technical foundation in the very field on which he intends to build his company.

An Investment Wave at the Intersection of AI and Life Sciences

This move does not come in a vacuum; it is part of a growing wave of investment at the intersection of AI and medical and pharmaceutical research. In the same week, Chai Discovery — a startup developing AI models to predict molecular interactions — announced the close of a $400 million funding round at a valuation of $3.8 billion. Notably, one of its co-founders was also a researcher at OpenAI. In the same vein, Isomorphic Labs, the spinout from Google DeepMind specializing in the same field, raised a Series B of $2.1 billion last May.

Broader Implications for the AI Market

These developments reveal two key trends worth watching:

• Talent migration from the lab to the market: Researchers at major AI labs are increasingly transitioning into founders of specialized startups, leveraging their technical expertise in high-impact application domains.
• Betting on drug discovery: Investors see enormous opportunity in this sector given the scale of global pharmaceutical R&D spending and AI's potential to compress development cycles from decades to years.

Actual success will ultimately depend on these models' ability to deliver clinically verifiable discoveries — the real challenge that will determine whether these massive investments translate into treatments that actually reach patients.

✦ بقلم فريق دروب أيديا